A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

NCT ID: NCT04435652

Last Updated: 2020-06-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 492 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-01
• Study Completion Date: 2022-11-30

Brief Summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.

Conditions

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: Cohort A

Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.

Group Type: EXPERIMENTAL

QL1604

Intervention Type: DRUG

3mg/kg, D1,8,15,Q4w, IV infusion

Nab-paclitaxel

Intervention Type: DRUG

100mg/m2, D1,8,15,Q4w, IV infusion

Experimental: Cohort B-arm1

Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.

Group Type: EXPERIMENTAL

QL1604

Intervention Type: DRUG

3mg/kg, D1,8,15,Q4w, IV infusion

Nab-paclitaxel

Intervention Type: DRUG

100mg/m2, D1,8,15,Q4w, IV infusion

Experimental: Cohort B-arm2

Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Paclitaxel

Intervention Type: DRUG

80mg/m2, D1,8,15,Q4w, IV infusion

Interventions

QL1604

3mg/kg, D1,8,15,Q4w, IV infusion

Intervention Type: DRUG

Nab-paclitaxel

100mg/m2, D1,8,15,Q4w, IV infusion

Intervention Type: DRUG

Paclitaxel

80mg/m2, D1,8,15,Q4w, IV infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Volunteer to participate in this clinical study; Completely understand and know this study as well as sign the informed consent form (ICF);

2. Age ≥ 18 years and ≤ 80 years when ICF is signed;

3. Have histologically or cytologically confirmed diagnosis of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma(G/GEJC).

4. Eastern Cooperative Oncology Group performance status of 0 or 1;

5. Life expectancy of at least 12 weeks;

6. Have measurable disease as defined by RECIST 1.1 as determined by the investigator;

7. Be willing to provide newly-obtained or paraffin-embedded tissue for PD-L1 and other biomarker analysis;

8. HER-2/neu negative；

9. Female subjects of childbearing potential should have a negative serum human chorionic gonadotropin(HCG) test within 7 days prior to receiving the first dose of study medication and are not breastfeeding;

10. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 180 days after last dose.

Exclusion Criteria

1. Has non-G/GEJC such as squamous cell carcinoma, adenosquamous carcinoma, undifferentiated gastric cancer;

2. Known allergy or hypersensitivity to QL1604/nab-paclitaxel/paclitaxel or any components used in the preparation;

3. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease disease-relieving drugs, corticosteroids or immunosuppressant）;

4. Has a diagnosis of immunodeficiency or received systemic steroid therapy （>10mg daily of prednisone or equivalent drug）or any other form of immunosuppressive therapy within 14 days prior to the planned start of study therapy；

5. Subjects who have received radiotherapy, chemotherapy, monoclonal antibodies,targeted therapy, other anti-tumor treatments,or participating in other clinical studies is less than 4 weeks before the first dose of trial treatment;

6. Has a known additional malignancy that is progressing or requires active treatment in past 3 years;

7. Subjects with known central nervous system (CNS) metastasis;

8. Has a history of pneumonitis that required steroids in past 3 years;

9. Has an active infection requiring systemic therapy；

10. Subjects with the history of Human Immunodeficiency Virus (HIV)、acquired, congenital immunodeficiency diseases、organ transplant;

11. Has hepatitis B surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive and HBV deoxyribonucleic acid (HBV DNA) >1000 copies/mL, or hepatitis C virus antibody positive;

12. Has received a live vaccine within 30 days of the planned start of study therapy；

13. Has received prior immune checkpoint inhibitors;

14. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;

15. Subjects with uncontrollable cardiac diseases;

16. Has accompanying diseases that seriously endanger the subject's safety or affect the study by the investigator;

17. Has any condition that increases the risk, interferes with the study results by the investigator, or investigators/sponsor consider the subjects are not suitable for this trial;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Cancer Hospital

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Shunjiang Yu, CMO

Role: CONTACT

shunjiang.yu@qilu-pharma.com

0531-83129659

Weijian Guo, Professor

Role: CONTACT

021-64175590

Other Identifiers

QL1604-302

Identifier Type: -

Identifier Source: org_study_id